EA021284B1 - Антитела и их производные - Google Patents

Антитела и их производные Download PDF

Info

Publication number
EA021284B1
EA021284B1 EA201070888A EA201070888A EA021284B1 EA 021284 B1 EA021284 B1 EA 021284B1 EA 201070888 A EA201070888 A EA 201070888A EA 201070888 A EA201070888 A EA 201070888A EA 021284 B1 EA021284 B1 EA 021284B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
zeg
pain
antibodies
derivative
Prior art date
Application number
EA201070888A
Other languages
English (en)
Russian (ru)
Other versions
EA201070888A1 (ru
Inventor
Фабио Бениньи
Даниель Д'Амбросио
Original Assignee
Лей Лайн Дженомикс С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лей Лайн Дженомикс С.П.А. filed Critical Лей Лайн Дженомикс С.П.А.
Publication of EA201070888A1 publication Critical patent/EA201070888A1/ru
Publication of EA021284B1 publication Critical patent/EA021284B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/30—Fuel from waste, e.g. synthetic alcohol or diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
EA201070888A 2008-02-04 2009-02-04 Антитела и их производные EA021284B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2599508P 2008-02-04 2008-02-04
PCT/EP2009/051285 WO2009098238A1 (en) 2008-02-04 2009-02-04 Anti-trka antibodies and derivatives thereof

Publications (2)

Publication Number Publication Date
EA201070888A1 EA201070888A1 (ru) 2011-04-29
EA021284B1 true EA021284B1 (ru) 2015-05-29

Family

ID=40521960

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070888A EA021284B1 (ru) 2008-02-04 2009-02-04 Антитела и их производные

Country Status (20)

Country Link
US (1) US9751947B2 (https=)
EP (1) EP2252633B9 (https=)
JP (1) JP5719596B2 (https=)
KR (1) KR101782857B1 (https=)
CN (1) CN101939337B (https=)
AP (1) AP2929A (https=)
AU (1) AU2009211340B2 (https=)
BR (1) BRPI0905955A8 (https=)
CA (1) CA2713786A1 (https=)
DK (1) DK2252633T3 (https=)
EA (1) EA021284B1 (https=)
ES (1) ES2435917T3 (https=)
IL (1) IL207390A (https=)
MX (1) MX2010008571A (https=)
MY (1) MY191348A (https=)
NZ (1) NZ587701A (https=)
PL (1) PL2252633T3 (https=)
PT (1) PT2252633E (https=)
WO (1) WO2009098238A1 (https=)
ZA (1) ZA201006218B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
EP2252633B9 (en) 2008-02-04 2014-02-19 Lay Line Genomics S.P.A. Anti-trka antibodies and derivatives thereof
WO2010029497A1 (en) * 2008-09-12 2010-03-18 Pfizer Limited Treatment of endometriosis
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
EP2646468B1 (en) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf compositions and use thereof
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US20150183885A1 (en) * 2012-06-08 2015-07-02 Glenmark Pharmaceuticals S.A. Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
ES2666126T3 (es) * 2012-06-08 2018-05-03 Glenmark Pharmaceuticals S.A. Anticuerpos anti-TrkA humanizados con sustituciones de aminoácidos
EP2674439B1 (en) 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
US10793634B2 (en) * 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
CN109628425A (zh) * 2019-01-02 2019-04-16 周越 一种人原肌球蛋白受体激酶a突变体及应用
EP3976657A4 (en) * 2019-05-30 2023-07-05 Sunshine Lake Pharma Co., Ltd. ANTI-TRKA ANTIBODIES AND USES THEREOF
EP4069745A4 (en) * 2019-11-06 2024-05-29 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR 1 TARGETING
JP7837873B2 (ja) * 2020-11-20 2026-03-31 サンシャイン・レイク・ファーマ・カンパニー・リミテッド ヒト化抗ＴｒｋＡ抗体及びその使用
CN112961244B (zh) * 2021-02-28 2023-08-29 熙源安健医药（上海）有限公司 抗TrkA抗体或其抗原结合片段、其制备方法和应用
JP2025503539A (ja) 2021-12-28 2025-02-04 ４ビー テクノロジーズ（スーヂョウ） リミテッド ＴｒｋＡ抗体とその応用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073344A2 (en) * 1999-05-26 2000-12-07 Lay Line Genomics Spa Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules
WO2005061540A2 (en) * 2003-12-24 2005-07-07 Lay Line Genomics S.P.A. Method for the humanization of antibodies and humanized antibodies thereby obtained
WO2006131951A2 (en) * 2005-06-07 2006-12-14 Pangenetics B.V. MOLECULES THAT ARE ABLE TO INHIBIT THE BINDING BETWEEN NGF AND THE TrkA RECEPTOR AS ANALGESICS WITH PROLONGED EFFECT
WO2006137106A2 (en) * 2005-06-24 2006-12-28 Lay Line Genomics S.P.A Method for the potentiation of opioid analgesics effects on pain

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
JP2001519666A (ja) 1997-04-10 2001-10-23 ジェネティックス・インスチチュート・インコーポレーテッド 分泌発現配列タグ（ｓＥＳＴｓ）
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB2340334B (en) * 1998-07-29 2003-06-25 Ericsson Telefon Ab L M Telephone apparatus
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
ZA200502612B (en) 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
EP3372614B1 (en) 2004-04-07 2022-06-08 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP2252633B9 (en) 2008-02-04 2014-02-19 Lay Line Genomics S.P.A. Anti-trka antibodies and derivatives thereof
EP2307042B1 (en) 2008-06-25 2014-03-26 H. Lundbeck A/S Modulation of the trpv : vps10p-domain receptor system for the treatment of pain

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073344A2 (en) * 1999-05-26 2000-12-07 Lay Line Genomics Spa Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules
WO2005061540A2 (en) * 2003-12-24 2005-07-07 Lay Line Genomics S.P.A. Method for the humanization of antibodies and humanized antibodies thereby obtained
WO2006131951A2 (en) * 2005-06-07 2006-12-14 Pangenetics B.V. MOLECULES THAT ARE ABLE TO INHIBIT THE BINDING BETWEEN NGF AND THE TrkA RECEPTOR AS ANALGESICS WITH PROLONGED EFFECT
WO2006137106A2 (en) * 2005-06-24 2006-12-28 Lay Line Genomics S.P.A Method for the potentiation of opioid analgesics effects on pain

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CATTANEO A. ET AL.: "FUNCTIONAL BLOCKADE OF TYROSINE KINASE A IN THE RAT BASAL FOREBRAINBY A NOVEL ANTAGONISTIC ANTI-RECEPTOR MONOCLONAL ANTIBODY". JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, vol. 19, no. 22, 15 November, 1999 (1999-11-15), pages 9687-9697, XP000945020, ISSN: 0270-6474, page 9688, left-hand column, paragraph 2 - paragraph 3, page 9694, right-hand column, paragraph 3, page 9695, left-hand column, paragraph 2, page 9690, left-hand column, paragraph 2; figure 1 *
UGOLINI GABRIELE ET AL.: "The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain". PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 20 FEB 2007, vol. 104, no. 8, 20 February 2007 (2007-02-20), pages 2985-2990, XP002523974, ISSN: 0027-8424, page 2986, right-hand column - page 2989, right-hand column, paragraph 3 *

Also Published As

Publication number Publication date
PL2252633T3 (pl) 2014-02-28
EP2252633B1 (en) 2013-08-14
BRPI0905955A8 (pt) 2018-05-08
US9751947B2 (en) 2017-09-05
JP5719596B2 (ja) 2015-05-20
JP2011514314A (ja) 2011-05-06
AU2009211340B2 (en) 2013-09-12
DK2252633T3 (da) 2013-11-11
EA201070888A1 (ru) 2011-04-29
AP2929A (en) 2014-06-30
KR101782857B1 (ko) 2017-09-28
IL207390A (en) 2015-06-30
BRPI0905955A2 (pt) 2015-08-04
US20110145941A1 (en) 2011-06-16
CN101939337A (zh) 2011-01-05
AP2010005379A0 (en) 2010-08-31
EP2252633B9 (en) 2014-02-19
ES2435917T3 (es) 2013-12-26
WO2009098238A1 (en) 2009-08-13
NZ587701A (en) 2013-03-28
CN101939337B (zh) 2016-03-09
AU2009211340A1 (en) 2009-08-13
ZA201006218B (en) 2011-08-31
MY191348A (en) 2022-06-17
MX2010008571A (es) 2010-12-02
HK1150314A1 (en) 2011-11-25
KR20100114536A (ko) 2010-10-25
EP2252633A1 (en) 2010-11-24
CA2713786A1 (en) 2009-08-13
IL207390A0 (en) 2010-12-30
PT2252633E (pt) 2013-11-19
ES2435917T9 (es) 2014-04-02

Similar Documents

Publication Publication Date Title
EA021284B1 (ru) Антитела и их производные
JP6749235B2 (ja) Ｇｌｐ−１ｒに特異的に結合する抗体およびそのｇｌｐ−１との融合タンパク質
TWI264467B (en) Human anti-CD40 antibodies and methods of making and using same
ES2704411T3 (es) Proteínas de fusión inmunomoduladoras y procedimientos de fabricación de las mismas
EA029277B1 (ru) Vegf-связывающая молекула, кодирующая эту молекулу молекула нуклеиновой кислоты (нк), вектор, содержащий молекулу нк, клетка-хозяин, содержащая молекулу нк или вектор, фармацевтическая композиция, содержащая vegf-связывающую молекулу, и способ производства vegf-связывающей молекулы
WO2016023001A1 (en) Multispecific high affinity pd-1 agents and methods of use
EA026129B1 (ru) АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ ЧЕЛОВЕКА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С β-КЛОТО, РЕЦЕПТОРАМИ FGF И ИХ КОМПЛЕКСАМИ
RS66303B1 (sr) Upotreba anti-cgrp antitela i fragmenata antitela za sprečavanje ili inhibiranje fotofobije ili odbojnosti prema svetlu kod subjekata kojima je to potrebno, naročito kod subjekata koji pate od migrene
EP0910408A1 (en) DELIVERY SYSTEM USING mAb 3E10 AND MUTANTS AND/OR FUNCTIONAL FRAGMENTS THEREOF
JP7539834B2 (ja) ガレクチン－３に対する抗体及びその使用方法
KR102805186B1 (ko) Gpc3에 특이적인 항체 및 이의 용도
CN103965363A (zh) 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途
JP2010503381A (ja) プロテアーゼ活性化受容体１（ｐａｒ１）のアンタゴニスト
MX2010007551A (es) Antagonistas de la cadherina-11 y metodos para el tratamiento de trastornos inflamatorios de las articulacion.
JP2019509759A (ja) 抗ｐｄ−１抗体及びその使用
MX2010012812A (es) Metodos de tratamiento que utilizan proteinas de union del receptor de la interleucina-21.
WO2016127104A2 (en) Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
KR102800024B1 (ko) 항-ｍｙｌ9 항체
US20240343788A1 (en) Novel bifunctional multispecific antagonists capable of inhibiting multiple ligands of tgf-beta family and uses thereof
JP2013199492A (ja) Ｆｄｆ０３抗体およびそれの使用
WO2018136163A2 (en) Tandem apoa-1 fusion polypeptides
Trakas et al. Conjugation of acetylcholine receptor-protecting Fab fragments with polyethylene glycol results in a prolonged half-life in the circulation and reduced immunogenicity
US20240218337A1 (en) Fusion protein targeting pd-l1 and neutralizing gas6 and uses thereof
OA18848A (en) Anti - TRKA antibodies and derivatives thereof.
WO2006026172A2 (en) Use of soluble cd26 as inhibitor of angiogenesis and inflammation